These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2870891)

  • 1. Nizatidine, an H2-blocker. Its metabolism and disposition in man.
    Knadler MP; Bergstrom RF; Callaghan JT; Rubin A
    Drug Metab Dispos; 1986; 14(2):175-82. PubMed ID: 2870891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: application to the analysis of ranitidine and its metabolites in human volunteers.
    Ashiru DA; Patel R; Basit AW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Dec; 860(2):235-40. PubMed ID: 18006395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of famotidine in man.
    Kroemer H; Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
    Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.
    Lin TM; Evans DC; Warrick MW; Pioch RP
    J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxic convulsions induced by histamine H2 receptor antagonists in mice.
    Shimokawa M; Yamamoto K; Kawakami J; Sawada Y; Iga T
    Toxicol Appl Pharmacol; 1996 Feb; 136(2):317-23. PubMed ID: 8619239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam.
    Klotz U; Gottlieb W; Keohane PP; Dammann HG
    J Clin Pharmacol; 1987 Mar; 27(3):210-2. PubMed ID: 2890666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration.
    Pace F; Colombo E; Ferrara A; Prada A; Rocca F; Bianchi Porro G
    Am J Gastroenterol; 1988 Jun; 83(6):643-5. PubMed ID: 2897784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
    Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
    Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous nizatidine kinetics and acid suppression.
    Callaghan JT; Bergstrom RF; Obermeyer BD; King EP; Offen WW
    Clin Pharmacol Ther; 1985 Feb; 37(2):162-5. PubMed ID: 2857117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.
    Lima M; Holdcroft C
    Nurse Pract; 1989 Feb; 14(2):41-2. PubMed ID: 2564655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of effect of nizatidine on drug metabolism.
    Klotz U
    Scand J Gastroenterol Suppl; 1987; 136():18-23. PubMed ID: 2892251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacokinetic profile of nizatidine in man.
    Callaghan JT; Bergstrom RF; Rubin A; Chernish S; Crabtree R; Knadler MP; Obermeyer B; Offen WW; Schneck DW; Aronoff G
    Scand J Gastroenterol Suppl; 1987; 136():9-17. PubMed ID: 2892261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPLC reveals famotidine in the urine up to five days after a single 20 mg oral dose.
    Bologna M; Napolitano T; Biordi L; Carlucci G
    Drugs Exp Clin Res; 1988; 14(6):419-21. PubMed ID: 2905638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption studies of the H2-blocker nizatidine.
    Knadler MP; Bergstrom RF; Callaghan JT; Obermeyer BD; Rubin A
    Clin Pharmacol Ther; 1987 Nov; 42(5):514-20. PubMed ID: 2890459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide.
    Itoh H; Naito T; Takeyama M
    J Pharm Pharmacol; 2002 Nov; 54(11):1559-63. PubMed ID: 12495560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ranitidine and nizatidine in very elderly patients.
    Sasaki M; Sudoh T; Fujimura A
    Am J Ther; 2005; 12(3):223-5. PubMed ID: 15891265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin.
    Hammond JB; Offen WW
    Am J Gastroenterol; 1988 Jan; 83(1):32-6. PubMed ID: 2892392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The disposition of l-3-[(dimethylamino)-(m-dioxan-5-yl)methyl]pyridine in man.
    Rubin A; Dhahir PH; Crabtree RE; Henry DP
    Drug Metab Dispos; 1979; 7(3):149-54. PubMed ID: 38085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma.
    Wu SM; Ho YH; Wu HL; Chen SH; Ko HS
    Electrophoresis; 2001 Aug; 22(13):2717-22. PubMed ID: 11545397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.